Manuscript Communication

Dear Dr. Chen,

Thank you for submitting your manuscript "Novel Approaches to CRISPR Gene Editing in Cancer Treatment" to Nature Biotechnology. I am pleased to inform you that your manuscript has been sent out for peer review.

We have assigned two reviewers with expertise in CRISPR technology and cancer therapeutics. You can expect to receive their feedback within the next 3-4 weeks.

Best regards,
Dr. Sarah Johnson
Associate Editor, Nature Biotechnology

This manuscript presents a novel approach to CRISPR gene editing for cancer treatment. The methodology is sound and the results are promising, but I have several concerns that should be addressed:

1. The off-target effects analysis is incomplete. The authors should provide more comprehensive data on potential off-target sites.
2. The in vivo experiments use a limited number of animal models. Additional models would strengthen the conclusions.
3. The discussion should address the potential immunogenicity of the proposed delivery system more thoroughly.

I recommend revision to address these issues before publication.

The authors present an innovative approach to CRISPR-based cancer therapy. The manuscript is well-written and the experimental design is robust. I have a few suggestions for improvement:

1. The mechanistic studies in Figure 3 could be strengthened with additional biochemical assays.
2. The clinical implications section would benefit from a more detailed discussion of potential translation barriers.
3. Minor formatting issues in the references section need correction.

Overall, this is an excellent study that merits publication after minor revisions.